(NYSE:AXTA), PHILADELPHIA, Jan. 23, 2025 (GLOBE NEWSWIRE) — Axalta Coating Systems Ltd. (NYSE: AXTA) (“Axalta” or the “Company”), a leading global coatings company, today announced that Tim Bowes has been appointed President, Global Industrial Coatings, effective January 27, 2025. Mr. Bowes will succeed Shelley Bausch who will be stepping down from her role. Most recently, […]

(TSX:BSX),(OTC US:BSXGF),(Other OTC:BSXGF), TORONTO, Jan. 23, 2025 (GLOBE NEWSWIRE) — Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX, OTCQB:BSXGF) reports that the Federal Court of Appeals in Brasilia (TRF1) has unanimously ruled that the Secretariat of Environment and Sustainability of the State of Para (SEMAS) will be the competent authority for the environmental

(NasdaqGM:IXHL), Demonstrated bioavailability of IHL-42X, Incannex's proprietary combination formulation, confirming delivery of both dronabinol and acetazolamide Achieved similar PK and equivalent total drug exposure levels of IHL-42X and the reference listed drugs (RLD) for dronabinol and acetazolamide, building a scientific bridge to established safety and toxicology data with the potential to support a future FDA

(NASDAQ:RCAT), SAN JUAN, Puerto Rico, Jan. 23, 2025 (GLOBE NEWSWIRE) — Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or the “Company”), a drone technology company integrating robotic hardware and software for military, government, and commercial operations, today announced it has secured new orders for its Edge 130 drone from the Army National Guard and

ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions First drug candidate to enter the clinic that utilizes the company's proprietary ATTOBODY platform, which offers best-in-class potency and unconstrained engineering potential FREMONT, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) — Attovia

(NASDAQ:IFRX), JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in the Guggenheim SMID Cap Biotech Conference, to be held February 5 – 6, 2025 in New York, NY. About InflaRx InflaRx (Nasdaq: IFRX) is

(NASDAQ:SYBT), LOUISVILLE, Ky., Jan. 23, 2025 (GLOBE NEWSWIRE) — Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, central, eastern and northern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today announced that Ja Hillebrand, Chairman and CEO, and T. Clay

NEW YORK, NY / ACCESSWIRE / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc.") (NASDAQ:NMRA) concerning possible violations of federal securities laws. On January 2, 2025, Neumora announced its experimental depression treatment failed in the first of three studies planned by

NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo Nordisk A/S ("Novo Nordisk A/S") (NYSE:NVO) concerning possible violations of federal securities laws. On December 20, 2024, Novo issued a press release announcing the below-expected results of their "REDEFINE 1" trial,

NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Signet Jewelers Limited ("Signet") (NYSE:SIG) concerning possible violations of federal securities laws. On January 14, 2025, Signet issued a press release announcing the company’s holiday sales results, comprising the 10-week period ending